Transfusion-associated graft versus host disease primary prevention
|
Transfusion-associated graft versus host disease Microchapters |
|
Differentiating Transfusion-associated graft versus host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Transfusion-associated graft versus host disease primary prevention On the Web |
|
American Roentgen Ray Society Images of Transfusion-associated graft versus host disease primary prevention |
|
FDA on Transfusion-associated graft versus host disease primary prevention |
|
CDC on Transfusion-associated graft versus host disease primary prevention |
|
Transfusion-associated graft versus host disease primary prevention in the news |
|
Blogs on Transfusion-associated graft versus host disease primary prevention |
|
Directions to Hospitals Treating Transfusion-associated graft versus host disease |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Primary Prevention
Prevention includes gamma irradiation of the lymphocyte-containing blood products. This procedure should be performed in transfusions when:
- the recipient is immunocompromised
- the blood components are from a family donor
- HLA-matched platelets are transferred.
Another means of prevention is the use of third- or fourth-generation leukoreduction filters, although the efficacy of this procedure has not yet been documented.